Please contact our sales representative to learn more information about this reagents.
Background
Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer, it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.